Yes, ‘mentioned’ in that the known studies have been reviewed, and in reading it one finds: the fact that a significant concentration of the drug in lung tissue could only be achieved if one ingests 100 times the dose level considered safe for use in humans and even at that dosage plasma concentration was less than half what is needed for effectiveness against Covid-19, and there was no statistically significant difference found between it and the placebo, among other findings...
From that page:
“Ivermectin has been shown to inhibit replication of SARS-CoV-2 in cell cultures.9 However, pharmacokinetic and pharmacodynamic studies suggest that achieving the plasma concentrations necessary for the antiviral efficacy detected in vitro would require administration of doses up to 100-fold higher than those approved for use in humans.10,11Although ivermectin appears to accumulate in lung tissue, predicted systemic plasma and lung tissue concentrations are much lower than 2 µM, the half-maximal inhibitory concentration (IC50) observed in vitro for ivermectin against SARS-CoV-2.12-15 Subcutaneous administration of ivermectin 400 µg/kg had no effect on SARS-CoV-2 viral loads in hamsters.16 However, there was a reduction in olfactory deficit (measured using a food-finding test) and a reduction in the interleukin (IL)-6:IL-10 ratio in lung tissues.
The safety and efficacy of ivermectin for the prevention and treatment of COVID-19 have been evaluated in clinical trials and observational cohorts. Summaries of the studies that informed The COVID-19 Treatment Guidelines Panel’s (the Panel) recommendation can be found in
Table 4c. The Panel reviewed additional studies, but these studies are not summarized in Table 4c because they have study design limitations or results that make them less definitive and informative.
Recommendation
- The Panel recommends againstthe use of ivermectin for the treatment of COVID-19, except in clinical trials (AIIa).
Rationale
The results of several randomized trials and retrospective cohort studies of ivermectin use in patients with COVID-19 have been published in peer-reviewed journals or have been made available as manuscripts ahead of peer review. Most of these studies, especially studies completed earlier in the pandemic, had incomplete information and significant methodological limitations, which made excluding common causes of bias difficult. Many of these studies have not been peer reviewed, and some have now been retracted”
